Yes, ertapenem can be safely given to patients with penicillin allergy
Carbapenems, including ertapenem, may be administered to patients with a history of penicillin allergy without prior testing or additional precautions in most cases. 1
Evidence-Based Recommendation
The 2022 Drug Allergy Practice Parameter provides a conditional recommendation with moderate certainty of evidence that carbapenems can be given to penicillin-allergic patients without testing 1. This is supported by compelling data:
Cross-Reactivity Risk is Extremely Low
- Overall carbapenem cross-reactivity rate: 0.87% (95% CI: 0.32-2.32%) across 1,127 penicillin-allergic patients 1, 2
- Among patients with confirmed positive penicillin skin tests (n=295), only 0.3% had reactions to carbapenems that were potentially IgE-mediated 1
- A prospective study of 211 patients with skin test-confirmed penicillin allergy showed 100% tolerated carbapenems 1
- Research specifically on ertapenem showed 35 of 36 β-lactam-allergic patients (97%) tolerated full-dose challenges 3
Important Caveats
The one exception where caution is warranted: Patients with severe delayed cutaneous reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS) or organ-involved reactions to penicillins should not receive carbapenems without prior testing 1.
Clinical Approach
For patients with immediate-type penicillin allergy (urticaria, anaphylaxis):
- Administer ertapenem directly without skin testing
- No graded challenge needed
- Standard monitoring as with any new medication
For patients with non-severe delayed reactions (maculopapular rash):
- Administer ertapenem directly without testing
- Standard monitoring
For patients with multiple drug allergies or significant anxiety:
- Consider graded drug challenge in a monitored setting 1
FDA Label Considerations
The FDA label for ertapenem includes a warning that "individuals with a history of penicillin hypersensitivity have experienced severe hypersensitivity reactions when treated with another beta-lactam" and recommends "careful inquiry" before initiating therapy 4. However, this generic warning predates the robust guideline evidence showing minimal cross-reactivity.
The guideline evidence should take precedence over the FDA's cautionary language, as it is based on systematic reviews and prospective studies demonstrating safety 1.
Practical Implementation
The Dutch SWAB 2023 guidelines echo these recommendations, stating carbapenems can be used in penicillin-allergic patients "irrespective of severity or time since the index reaction" 5. This represents international consensus on carbapenem safety in this population.
Bottom line: The outdated practice of avoiding all carbapenems in penicillin-allergic patients should be abandoned given the very low (<1%) cross-reactivity rate 3, 6. For patients requiring ertapenem, proceed with administration after documenting the allergy history to exclude severe delayed reactions.